Barzolvolimab
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria[1].
Product Specifications
CAS Number
2438203-51-9
Product Name Alternative
CDX-0159; CDX-0158
UNSPSC
12352203
Target
C-Kit
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/barzolvolimab.html
Purity
99.83
Solubility
H2O
Smiles
[Barzolvolimab]
Molecular Weight
(145.1 kDa)
References & Citations
[1]Terhorst-Molawi D, et, al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2022 Nov 16.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC681203-100 1x 100 µL
Smooth Muscle Actin (ACTA2/791 +1A4), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 